Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Lahner, B. Annibale, G. Fave (2009)
Systematic review: impaired drug absorption related to the co‐administration of antisecretory therapyAlimentary Pharmacology & Therapeutics, 29
G. Guyatt, E. Akl, M. Crowther, D. Gutterman, Holger nemann (2012)
Executive Summary Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
(2012)
AGGRENOX (aspirin/extended-release dipyridamole) capsules prescribing information 2011 (online). http://bidocs.boehringer-ingelheim
G Born, C Patrono (2006)
Antiplatelet drugsBr J Pharmacol, 147
H. Derendorf, C. VanderMaelen, R. Brickl, T. Macgregor, W. Eisert (2005)
Dipyridamole Bioavailability in Subjects With Reduced Gastric AcidityThe Journal of Clinical Pharmacology, 45
S. Bode-Böger, Rainer Böger, M. Schubert, Jürgen Frölich (1998)
Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjectsEuropean Journal of Clinical Pharmacology, 54
Deepak Bhatt, J. Scheiman, N. Abraham, E. Antman, Francis Chan, C. Furberg, David Johnson, K. Mahaffey, E. Quigley, R. Harrington, E. Bates, C. Bridges, M. Eisenberg, V. Ferrari, M. Hlatky, S. Kaul, J. Lindner, D. Moliterno, D. Mukherjee, R. Schofield, R. Rosenson, J. Stein, H. Weitz, D. Wesley (2008)
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Journal of the American College of Cardiology, 52 18
PA Gurbel, KP Bliden, J DiChiara (2007)
Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) studyCirculation, 115
(2007)
CHAPTER 63 – Dipyridamole
Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations
K. Furie (2011)
Response to Letter by Naylor Regarding Article, “Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association”Stroke, 42
M. Gilard, B. Arnaud, J. Cornily, G. Gal, K. Lacut, G. Calvez, J. Mansourati, D. Mottier, J. Abgrall, J. Boschat (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.Journal of the American College of Cardiology, 51 3
W. Kernan, B. Ovbiagele, Vice Chair, Henry Black, Dawn Bravata, M. Chimowitz, Michael Ezekowitz, Margaret Fang, M. Fisher, K. Furie, Donald Heck, S. Claiborne, Clay Johnston, S. Kasner, S. Kittner, Pamela Mitchell, Michael Rich, D. Richardson, L. Schwamm, John Wilson (2014)
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke, 45 7
(2007)
Dipyridamole. In: Michelson AD (ed) Platelets, 2nd edn
S. Dunn, Tracy Macaulay (2011)
Drug-drug interactions associated with antiplatelet therapy.Cardiovascular & hematological agents in medicinal chemistry, 9 4
V. Ancrenaz, Y. Daali, P. Fontana, M. Besson, C. Samer, P. Dayer, J. Desmeules (2010)
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.Current drug metabolism, 11 8
(2012)
PRILOSEC (omeprazole) delayed-release capsules 2012 (online)
Dermot Cox, A. Maree, Michelle Dooley, R. Conroy, M. Byrne, D. Fitzgerald (2006)
Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy VolunteersStroke, 37
European Stroke Organization (ESO) Guidelines for management of ischaemic stroke and transient ischaemic attack
P. Ho, T. Maddox, Li Wang, S. Fihn, R. Jesse, E. Peterson, J. Rumsfeld (2009)
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.JAMA, 301 9
K. Furie, S. Kasner, Vice Chair, Robert Adams, Gregory Albers, Ruth Bush, Susan Fagan, J. Halperin, S. Johnston, I. Katzan, W. Kernan, Pamela Mitchell, B. Ovbiagele, Y. Palesch, R. Sacco, L. Schwamm, S. Wassertheil-Smoller, Tanya Turan, Deidre Wentworth (2011)
Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association.Stroke, 42 1
(2012)
of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
Bliden Kp, Joseph Dichiara, Justin Newcomer, Willy Weng, N. Neerchal, S. Chaganti, A. Etherington, E. Topol, Donald Easton, R. Harrington, Pierre Amarenco, R. Califf, Carmen Graffagnino, Stephen Davis, James Ferguson, Desmond Fitzgerald, J. Granett, Ashfaq Shuaib, Pierre Théroux, K. Sigmon (2008)
Letter by Klein Regarding Article, "Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study"
(2012)
Persantine (dipyridamole USP) prescribing information 2006 (online)
Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations
D. Small, N. Farid, C. Payne, G. Weerakkody, Y. Li, J. Brandt, D. Salazar, K. Winters (2008)
Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and ClopidogrelThe Journal of Clinical Pharmacology, 48
Tanya Russell, R. Berardi, J. Barnett, Tami O'Sullivan, J. Wagner, J. Dressman (2004)
pH-Related Changes in the Absorption of Dipyridamole in the ElderlyPharmaceutical Research, 11
Am J Cardiovasc Drugs (2013) 13:113–120 DOI 10.1007/s40256-013-0018-3 OR IGINAL RESEARCH ARTIC L E Pharmacokinetics and Pharmacodynamics of the Antiplatelet Combination Aspirin (Acetylsalicylic Acid) Plus Extended-Release Dipyridamole Are Not Altered by Coadministration with the Potent CYP2C19 Inhibitor Omeprazole • • Elliot Offman Michael J. Schobelock • • Rolf Brickl Cam P. VanderMaelen Jerome Ehrlich Wolfgang Eisert Published online: 27 March 2013 Springer International Publishing Switzerland 2013 Abstract Participants Sixty healthy male and female volunteers Background The fixed-dose combination of aspirin aged 18–50 years were included in the study. (acetylsalicylic acid) 25 mg plus extended-release dipy- Intervention Participants were randomized to one of two ridamole 200 mg (ASA ? ER-DP) is used for long-term treatment sequences (ABCD or CDAB), each compris- secondary stroke prevention in patients who have experi- ing four 7-day treatments with a washout of C14 days enced non-cardioembolic stroke or transient ischemic between the second and third treatments. Treatment attack. Although the theoretical risk is low that the anti- A = ASA ? ER-DP 25 mg/200 mg (Aggrenox ) twice platelet activity of ASA ? ER-DP will be affected by daily (BID) alone; B = ASA ? ER-DP 25 mg/200 mg concomitant use of a proton pump
American Journal of Cardiovascular Drugs – Springer Journals
Published: Mar 27, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.